about
A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis dataUsing historical control information for the design and analysis of clinical trials with overdispersed count data.Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.Population pharmacokinetics of fingolimod phosphate in healthy participants.Rivastigmine exposure provided by a transdermal patch versus capsules.Model-based drug development in oncology: what's next?Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab.Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapyA continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxelFrom waterfall plots to spaghetti plots in early oncology clinical developmentAssociation Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-UpTherapeutically-induced stable disease in oncology early clinical trials
P50
Q30487222-A75D0417-4E20-49AC-8481-F24D7DE0D58FQ30588771-75B72A4E-24E3-4FC3-9BAD-5C99D7575412Q30636643-CB373D05-431A-4C54-8908-0D20530BFAA1Q35665759-40B94528-DDAF-45FA-B031-183240FAE11FQ38178093-B55161CA-8475-496D-AC90-7AAF9833980EQ38836780-D65E7B1D-7DE2-44FC-80F4-6752AA726497Q38982360-0EE963F9-6FEC-4CC9-B1E7-7C50BC75277CQ45171971-7575AEF1-AF86-48B3-8361-3B4B96D460F7Q46900675-A1E4EC46-0E2C-4D67-80D9-89C62CDEFAF1Q50752919-E10268A0-3509-43E7-A7AA-3F7D0224EB88Q53684267-F93E59E4-881E-4567-87B7-35B5BA3F110FQ64954722-645C4455-55EA-4A50-99A9-15EB3E1ADD21Q87263098-466E7ECD-4CBA-46CA-8B85-7514CD0237C6Q89145971-E8119BC5-E817-4391-AA78-7938E095F0D5Q92816024-D660E4C8-5855-473E-A12A-D0F40D3CCDFFQ93091840-8F9E41FD-7660-43C3-AAFE-8868EE78E39DQ96016590-5C04B468-6386-4888-B6E2-7679BA91517D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5685-1408
@en
name
Francois Mercier
@ast
Francois Mercier
@en
Francois Mercier
@es
Francois Mercier
@nl
type
label
Francois Mercier
@ast
Francois Mercier
@en
Francois Mercier
@es
Francois Mercier
@nl
prefLabel
Francois Mercier
@ast
Francois Mercier
@en
Francois Mercier
@es
Francois Mercier
@nl
P106
P31
P496
0000-0002-5685-1408